Botulinum neurotoxins
Material type:
TextSeries: Publication details: Heidelberg ; New York : Springer, c2013.Description: viii, 321 p. : ill. (some col.)ISBN: - 9783642335693
- QP632 B66B68
| Item type | Current library | Collection | Call number | Status | Barcode | |
|---|---|---|---|---|---|---|
Books
|
Directorate of Library Services General Collection | Shelf #2 | MED QP632.B66B68 (Browse shelf(Opens below)) | Available | 000000114697 |
Browsing Directorate of Library Services shelves, Shelving location: General Collection, Collection: Shelf #2 Close shelf browser (Hides shelf browser)
|
|
|
|
|
|
|
||
| MED QP609.P78P746 Proteases of infectious agents | MED QP624.5.D726 W54 Statistics for microarrays : | MED QP632.B66.B69 Botulinum toxin | MED QP632.B66B68 Botulinum neurotoxins | MED QP632.B66C555 Clinical uses of botulinum toxins / | MED QP632.B66C555 Clinical uses of botulinum toxins / | MED QP671.P6I5 porphyrins in human diseases |
The extremely potent substance botulinum neurotoxin (BoNT) has attracted much interest in diverse fields. Originally identified as cause for the rare but deadly disease botulism, military and terrorist intended to misuse this sophisticated molecule as biological weapon. This caused its classification as select agent category A by the Centers for Diseases Control and Prevention and the listing in the Biological and Toxin Weapons Convention. Later, the civilian use of BoNT as long acting peripheral muscle relaxant has turned this molecule into an indispensable pharmaceutical world wide with annual revenues >$1.5 billion--
There are no comments on this title.
